On October 29, 2024, the Food and Drug Administration approved asciminib (Scemblix, Novartis AG) for adults who have just been diagnosed with Philadelphia chromosome-positive chronic myeloid leukemi...
tyrosine-kinase-inhibitors
Targeted Therapy in Advanced Cancer: A Precision Approach to Treatment
Targeted therapy has significantly transformed the therapeutic options for advanced cancer in the field of oncology. Tar...
tyrosine-kinase-inhibitors
tyrosine-kinase-inhibitors